BRCAAway OS Update: Abiraterone + Olaparib Extends Survival by 5 Years in HRRm mCRPC

The BRCAAway trial brings strong new data on treating metastatic castration-resistant prostate cancer, or mCRPC, in patients with specific DNA repair defects known as homologous recombination repair mutations, or HRRm. This phase 2 study tested abiraterone alone, olaparib alone, or the two drugs together as first-line therapy. It focused on patients with germline or somatic mutations in BRCA1/2 or ATM genes. Earlier results already showed the combination greatly improved progression-free survival over single drugs or using them one after another. Now the trial reports full overall survival results from each group.

The study was multicenter and open-label. It randomized 61 eligible patients with progressive mCRPC and no prior use of PARP inhibitors or abiraterone. Patients split evenly into three arms. The combination arm showed the best results with a median overall survival of 68 months, 95% confidence interval (38 to not reached). Abiraterone alone OS was 28 months, while olaparib alone OS was 37 months.

These findings confirm the abiraterone plus prednisone and olaparib combo works well and adds more than 5 years of median survival over single agents or sequential use in mCRPC patients with BRCA1/2 or ATM changes.